Mr. Thomas joined Orchard Therapeutics, a biotechnology company dedicated to transforming the lives of patients with rare disorders through innovative gene therapies, as its Chief Financial Officer and Chief Business Officer in January 2018. Previously, Mr. Thomas served as the President and Chief Operating Officer of AMAG Pharmaceuticals, Inc. from 2015 to April 2017, and previously served as AMAG’s Executive Vice President and Chief Operating Officer from 2012 through 2015 and Executive Vice President, Chief Financial Officer and Treasurer from 2011 through 2012. Prior to joining AMAG, he served as Senior Vice President, Chief Operating Officer and Chief Financial Officer for Molecular Biometrics, Inc., a commercial stage medical diagnostics company, from 2008 to 2011. Prior to Molecular Biometrics, Mr. Thomas spent four years at Critical Therapeutics, Inc., a public biopharmaceutical company, from 2004 to 2008, where he was promoted to President in 2006 and Chief Executive Officer in 2006 from the position of Senior Vice President and Chief Financial Officer. He also served on the Board of Directors of Critical Therapeutics from 2006 to 2008. Prior to 2004, Mr. Thomas served as the Chief Financial Officer and Vice President of Finance and Investor Relations at Esperion Therapeutics, Inc., a public biopharmaceutical company. Mr. Thomas was a member of the Board of Directors of the Massachusetts Biotechnology Council from 2007 to 2015. In July 2017, Mr. Thomas was appointed to the Board of Directors at Spero Therapeutics, in this role he will also serve as the Chair of the Audit Committee. Mr. Thomas holds a B.B.A. from the University of Michigan, Ann Arbor.

Ms. Allen has served as our Chief Financial Officer since January 2013. Ms. Allen has over 20 years of financial leadership experience in the biotechnology industry at both publicly traded and private companies. From 2011 to 2012, she provided independent consulting services to biotechnology companies in a variety of areas, including interim CFO services, fundraising, deal structures, financial planning, organizational structure, investor relations and business development. Previously, from 2004 to 2011, Ms. Allen served as the Vice President of Finance, Treasurer and Principal Financial Officer of Alnylam Pharmaceuticals, Inc., a publicly traded biotechnology company, where she had significant interactions with the investment community and was influential in raising over $900 million via the company’s initial public offering, follow-on common stock offerings and multiple business development transactions with top-tier pharmaceutical companies. Prior to Alnylam, Ms. Allen was at Alkermes, Inc., a publicly traded biotechnology company, most recently as the Director of Finance. Ms. Allen began her career as an auditor at Deloitte & Touche, LLP. Ms. Allen also serves as a Director on the Board of Managers of Deciphera Pharmaceuticals and is also the Chair of their Audit Committee. Ms. Allen graduated summa cum laude from Bryant College with a B.S. in business administration.

Dr. Vath joined Zafgen in 2006 and brings over 20 years of experience in the biotechnology and pharmaceutical industries to his role as head of discovery and development. Prior to joining the company, Dr. Vath worked with established companies and new ventures to assess, develop and execute product development plans. As senior vice president of product development at Phylogix Inc., Dr. Vath created and implemented the corporate operational and R&D plan for the lead product in oncology-supportive care. Prior to Phylogix, he served as senior vice president of research at Praecis Pharmaceuticals where he led the R&D organization through multiple IND filings and a product approval. Dr. Vath also held roles as director of protein technologies at Millennium Pharmaceuticals and a lab head in development at Genetics Institute. Dr. Vath is a contributing author on numerous peer-reviewed journal publications and book chapters. Dr. Vath earned his Ph.D. in chemistry from the Massachusetts Institute of Technology and a B.S. in chemistry from Northeastern University.

Dr. Kim has served as our Chief Medical Officer since 2011. From 2001 to 2012, Dr. Kim was an Assistant Professor of Medicine, Division of Endocrinology/Metabolism, at the University of California, San Diego School of Medicine. From 2008 to 2011, Dr. Kim held multiple senior-level clinical and corporate affairs positions at Orexigen Therapeutics, Inc. a publicly-traded biopharmaceutical company focused on the treatment of obesity, including Senior Vice President, Head of Obesity/Metabolic Diseases; Senior Vice President, Corporate Development; and Senior Vice President, Medical Affairs and Communications. Prior to Orexigen, from 2007 to 2008, he was Chief Medical Officer and Vice President of Medical Affairs at EnteroMedics, Inc. a publicly traded medical device company, where he oversaw all aspects of clinical affairs and successfully implemented an initial public offering as part of the executive team in 2007. Previously, from 2001 to 2007, he held positions of increasing responsibility at Amylin Pharmaceuticals, Inc., a publicly traded biotechnology company, most recently as Executive Director, Corporate Strategy, where he managed corporate and business strategic planning spanning all commercial products, developmental drug candidates, corporate alliance partnership and manufacturing support. Dr. Kim holds an M.D. from the University of Health Sciences, The Chicago Medical School, an M.B.A from University of California, San Diego Rady School of Management and a B.S. in biology from the University of California at Los Angeles.

Dr. Hughes has more than 25 years of industry experience in the development and commercialization of pharmaceutical products and an extensive knowledge of the obesity and metabolic disease industry. Leading Zafgen since 2008 as CEO, Dr. Hughes currently serves as President, Chief Scientific Officer and a member of the company’s Board of Directors. From 1987 to 2008, Dr. Hughes held several positions at Novartis AG (and formerly Sandoz Pharmaceuticals) including Vice President and Global Head of the Cardiovascular and Metabolic Diseases Therapeutic area at the Novartis Institutes for BioMedical Research in Cambridge, MA. In these roles, he oversaw many drug discovery and development projects targeting obesity, diabetes and heart disease. As a scientist, Dr. Hughes led Novartis’ efforts to discover and develop its dipeptidyl peptidase IV inhibitor vildagliptin (Galvus®/Eucreas®), a drug used for the treatment of type 2 diabetes, currently approved in 70 countries.

Dr. Hughes is the author of over 40 peer-reviewed publications and is an inventor on numerous issued and pending patents related to the treatment of diabetes, cardiovascular disease and obesity. He currently serves as a member of the Board of Directors of miRagen Therapeutics, Inc., and is a member of several scientific and strategic advisory boards, including Broadview Ventures and Nimbus Therapeutics. Dr. Hughes holds a Ph.D. in nutritional biochemistry from Tufts University, an M.S. in Zoology from Virginia Polytechnic Institute & State University and a B.A. in biology from Franklin and Marshall College.